BioSpace News Archive

Lisata Therapeutics, Inc. announced today that it will report its financial results for the second quarter ended June 30, 2023, on Monday, August 14, 2023, after market trading and will host a conference call at 8:30 a.m. Eastern time the following morning.

Nexalin Technology, Inc. provided an update on the growing body of clinical data supporting the potential therapeutic benefits of its second-generation, 15 milliamp neurostimulation device, including the results of a study in patients with migraine headaches, which indicated a substantial and statistically significant benefit in patients.

After being known to have the largest stable in the Weight Management arena, Hi-Tech is poised to become the leader in a new category for focus, concentration, and productivity products with the launch of Adderex® XR.

GERO and FOXO Technologies Inc. , today announced the commencement of discussions to form a strategic collaboration between the two companies.

Inogen, Inc. today announced the introduction of the Rove 6™ portable oxygen concentrator in the United States with best in class 8-year expected service life.

BioCity Biopharma announced that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application for a Phase 1 study of BC3448.

XNK Therapeutics AB announced that the abstracts Harnessing the potential of autologous NK cells for immunotherapy of patients with advanced bladder cancer and Feeder-Free Expansion of Autologous Cytotoxic NK Cells for Acute Myeloid Leukemia Treatment will be presented at the 38th Meeting of the Society for Immunotherapy of Cancer in San Diego in November.

Duality Biologics Co. Ltd. announced that the company has expanded its collaboration with BioNTech SE to develop, manufacture and commercialize a third ADC candidate DB-1305 globally, excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region.

PacBio and GeneDx today announced a research collaboration with the University of Washington to study the capabilities of HiFi long-read whole genome sequencing (WGS) to increase diagnostic rates in pediatric patients with genetic conditions.

Twist Bioscience Corporation today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will participate in the Innovation Across Drug Discovery, Molecule Synthesis, & Precision Medicine panel at the UBS MedTech, Tools and Genomics Summit 2023 on Tuesday, August 15 at 2:00 p.m. Pacific Time.